Insider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 1,100 Shares of Stock

Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 1,100 shares of the stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $45.01, for a total value of $49,511.00. Following the transaction, the director now directly owns 318,652 shares in the company, valued at approximately $14,342,526.52. This represents a 0.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Pro-Dex Price Performance

PDEX stock traded up $1.87 during trading hours on Thursday, hitting $34.34. 29,150 shares of the stock traded hands, compared to its average volume of 33,327. The stock has a 50-day simple moving average of $46.46 and a 200 day simple moving average of $34.94. The company has a market cap of $111.98 million, a P/E ratio of 17.08 and a beta of 0.53. Pro-Dex, Inc. has a one year low of $16.18 and a one year high of $59.60. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 EPS for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. Equities analysts forecast that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Institutional Trading of Pro-Dex

Large investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of Pro-Dex by 34.9% during the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier's stock worth $119,000 after acquiring an additional 1,028 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Pro-Dex during the 4th quarter worth about $202,000. Renaissance Technologies LLC boosted its position in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier's stock worth $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. increased its stake in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier's stock valued at $406,000 after acquiring an additional 2,031 shares during the last quarter. Finally, Ritholtz Wealth Management bought a new position in shares of Pro-Dex during the fourth quarter worth $572,000. 15.28% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PDEX has been the topic of a number of recent analyst reports. Ascendiant Capital Markets boosted their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a "buy" rating in a report on Monday, November 11th. StockNews.com lowered Pro-Dex from a "strong-buy" rating to a "buy" rating in a research report on Monday.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.